1. Baka S, Zourla K, Kouskouni E, Makrakis E, Demeridou S, Tzanakaki D, Hassiakos D, Creatsas G. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in the follicular fluid of patients with polycystic ovaries undergoing in vitro fertilisation. In Vivo. 2010;24(3):293–6.
2. Baka S, Zourla K, Malamitsi-Puchner A, Makrakis E, Kaparos G, Demeridou S, Moustakarias T, Tzanakaki D, Hassiakos D, Kouskouni E. Intrafollicular levels of matrix metalloproteinases-2 and -9 in patients with polycystic ovaries are not associated with pregnancy rate during IVF cycle. In Vivo. 2009;23(1):89–92.
3. Bischof P, Meisser A, Campana A. Control of MMP-9 expression at the maternal-fetal interface. J Reprod Immunol. 2002;55(1–2):3–10.
4. Curry Jr TE, Song L, Wheeler SE. Cellular localization of gelatinases and tissue inhibitors of metalloproteinases during follicular growth, ovulation, and early luteal formation in the rat. Biol Reprod. 2001;65(3):855–65.
5. Curry Jr TE, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev. 2003;24(4):428–65.